ArticleProteins2022
Predicting residue-specific qualities of individual protein models using residual neural networks and graph neural networks.
Article in Proteins, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- EGG: Accuracy Estimation of Individual Multimeric Protein Models Using Deep Energy-Based Models and Graph Neural Networks.International journal of molecular sciences · 2024Article
- AlphaFold, allosteric, and orthosteric drug discovery: Ways forward.Drug discovery today · 2023Review
- Predicting residue-specific qualities of individual protein models using residual neural networks and graph neural networks.Proteins · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The estimation of protein model accuracy (EMA) or model quality assessment (QA) is important for protein structure prediction. An accurate EMA algorithm can guide the refinement of models or pick the best model or best parts of models from a pool of predicted tertiary structures. We developed two novel methods: MASS2 and LAW, for predicting residue-specific or local qualities of individual models, which incorporate residual neural networks and graph neural networks, respectively. These two methods use similar features extracted from protein models but different architectures of neural networks to predict the local accuracies of single models. MASS2 and LAW participated in the QA category of CASP14, and according to our evaluations based on CASP14 official criteria, MASS2 and LAW are the best and second-best methods based on the Z-scores of ASE/100, AUC, and ULR-1.F1. We also evaluated MASS2, LAW, and the residue-specific predicted deviations (between model and native structure) generated by AlphaFold2 on CASP14 AlphaFold2 tertiary structure (TS) models. LAW achieved comparable or better performances compared to the predicted deviations generated by AlphaFold2 on AlphaFold2 TS models, even though LAW was not trained on any AlphaFold2 TS models. Specifically, LAW performed better on AUC and ULR scores, and AlphaFold2 performed better on ASE scores. This means that AlphaFold2 is better at predicting deviations, but LAW is better at classifying accurate and inaccurate residues and detecting unreliable local regions. MASS2 and LAW can be freely accessed from http://dna.cs.miami.edu/MASS2-CASP14/ and http://dna.cs.miami.edu/LAW-CASP14/, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.